COLL

$23.73+0.21%visit website

COLLEGIUM PHARMACEUTICAL, INC

Market Cap

$773M

Live price × SEC shares (Jul 31, 2026)

Sector

Health Care

Industry

Pharmaceuticals

Beta (raw)

0.74

60mo monthly vs SPY

P/E (TTM)

18.7

TTM to Jun 2026 · diluted EPS

P/S (TTM)

1.0

TTM to Jun 2026 · revenue

P/B

2.5

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	209,361	205,449	193,520	199,878	808,208
Cost of revenue	80,190	77,071	76,274	89,586	323,121
Gross profit	129,171	128,378	117,246	110,292	485,087
Selling, general & administrative	67,103	67,640	86,350	106,594	327,687
Total operating expenses	67,084	67,621	86,350	106,594	327,649
Operating income	62,087	60,757	30,896	3,698	157,438
Interest expense	21,767	19,292	15,862	19,519	76,440
Pretax income	43,436	29,036	18,740	(13,532)	77,680
Income tax	11,929	12,073	4,244	1,519	29,765
Net income	31,507	16,963	14,496	(15,051)	47,915
EPS (basic) ($)	1.00	0.54	0.45	(0.46)	1.51
EPS (diluted) ($)	0.84	0.46	0.40	(0.46)	1.27
Weighted avg. shares (basic)	31,571	31,653	32,087	32,461
Weighted avg. shares (diluted)	39,440	40,076	40,066	32,461

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 6, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 46 more quarters, back to Mar 2014, with Tormere Pro.

Corporate Events (8-K)

13 filings in 12 months · 2 with priority itemsFull history →

Filed	Items	Filing
Oct 19, 2026 accepted 4:05 PM ET	1.02Agreement terminated	Document SEC ↗
Aug 13, 2026 accepted 7:30 AM ET	8.01Other events	Document SEC ↗
Aug 6, 2026 accepted 7:33 AM ET	2.02Earnings release7.01Reg FD disclosure	Document SEC ↗
Jun 30, 2026 accepted 4:05 PM ET	8-K/A 9.01Exhibits	Document SEC ↗
May 15, 2026 accepted 4:10 PM ET	5.07Shareholder vote	Document SEC ↗
May 12, 2026 accepted 7:43 AM ET	2.01Acquisition / disposition5.02Officer / director change7.01Reg FD disclosure	Document SEC ↗
May 7, 2026 accepted 7:33 AM ET	2.02Earnings release7.01Reg FD disclosure	Document SEC ↗
Apr 7, 2026 accepted 4:01 PM ET	5.02Officer / director change	Document SEC ↗
Mar 19, 2026 accepted 5:06 PM ET	1.01Material agreement7.01Reg FD disclosure	Document SEC ↗
Feb 26, 2026 accepted 7:32 AM ET	2.02Earnings release7.01Reg FD disclosure	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

67%

W/W +11.7pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-05-18	2026-05-20	Freund John Gordon	Director	Sale	20	$34.05	$681.00	84.0K	View
2026-05-15	2026-05-18	Freund John Gordon	Director	Sale	4,127	$34.54	$143K	84.0K	View
2026-05-13	2026-05-15	Lurker Nancy	Director	Sale	4,500	$35.97	$162K	18.0K	View
2026-05-11	2026-05-13	BOHLIN GAREN G	Director	Sale	8,700	$37.18	$323K	62.3K	View
2026-03-18	2026-03-20	Dieter David	EVP & General Counsel	Sale	14.0K	$34.92	$488K	77.1K	View

1–5 of 18

1 / 4

Recent News

Octave Specialty Group (OSG): A Counterintuitive Detractor Despite Strong Fundamentals

Yahoo · 2026-11-02

Collegium Pharmaceutical (COLL) Repositioning: Shifting Focus from Pain Management to ADHD

Yahoo · 2026-11-02

Robert Half (RHI) Surges on Temporary Staffing Stabilization and Easing AI Fears

Yahoo · 2026-11-02

Higher Energy Prices and Shortage Fears Drive Tidewater’s (TDW) Momentum

Yahoo · 2026-11-02

Qualys (QLYS) Surges Following Launch of AI-Driven Vulnerability Platform

Yahoo · 2026-11-02

What’s Driving PBF Energy’s (PBF) Cash Surge?

Yahoo · 2026-11-02

Operating Leverage and Financial Strength Anchor Champion Homes (SKY) Investment Thesis

Yahoo · 2026-10-30

Versigent (VGNT) is Unlocking Value Through Independent Growth and Capital Allocation

Yahoo · 2026-10-30

1 of Wall Street’s favorite stocks with promising prospects and 2 we turn down

Yahoo · 2026-10-30

Earnings Preview: Collegium Pharmaceutical (COLL) Q3 Earnings Expected to Decline

Yahoo · 2026-10-29

Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts

Yahoo · 2026-10-29

A planned 2027 soccer program will train coaches to better support kids with ADHD

Stock Titan · 2026-10-29

Collegium Pharmaceutical, Inc. (COLL) Stock Forecasts

Yahoo Finance · 2026-10-29

HCA Healthcare Q3 Earnings Beat Estimates on Higher Admissions

Yahoo · 2026-10-27

Q2 earnings highs and lows: Collegium Pharmaceutical (NASDAQ:COLL) vs the rest of the branded pharmaceuticals stocks

Yahoo Finance · 2026-10-26

Informational purposes only, not investment advice.

COLL

Financial Statements

Corporate Events (8-K)

Signals

Factor Profile

Recent News

COLLEGIUM PHARMACEUTICAL, INC (COLL)

Reporting Insiders

Factor Profile

Corporate Events (8-K)

Date	Insider	Type	Shares	Value
2026-05-18	Freund John Gordon	S	20	$681
2026-05-15	Freund John Gordon	S	4,127	$142,546.58
2026-05-13	Lurker Nancy	S	4,500	$161,860.95
2026-05-11	BOHLIN GAREN G	S	8,700	$323,491.23
2026-03-18	Dieter David	S	13,976	$488,099.22